# TScan Therapeutics

Source: https://onco.cc/companies/tscan/  
OnCo record `tscan` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TCR discovery company that cut 75% of staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours (PRAME, MAGE-A4).

## Summary

TScan Therapeutics, based in Waltham, Massachusetts, and listed as TCRX, is a TCR discovery company that cut 75 percent of its staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours against PRAME and MAGE-A4. It paused the phase 3 ALLOHA-2 trial of TSC-101 for lack of capital, has two in vivo TCR-T candidates entering IND-enabling studies with phase 1 planned for the fourth quarter of 2027, and previously ran a multiplexed autologous TCR-T basket study in solid tumours. OnCo links it to TCR-T cell therapy and in vivo CAR-T, to MAGE-A4 as a target, and to the idea of antibodies that see mutant KRAS and p53 fragments displayed on the cell surface. Whether a company can survive the gap between pausing a phase 3 and dosing a new first-in-human candidate is the open question its reorganisation raises. The TCR-T technology page carries the field.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Tags: pivot
- HQ: Waltham, MA
- Type: cell-therapy
- Website: https://www.tscan.com
- Ticker: TCRX

## Sources

- Strategic reorganisation: https://www.biospace.com/press-releases/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [MAGE-A4](https://onco.cc/targets/mage-a4/)
- ideas: [Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface](https://onco.cc/ideas/idea-bio1-pmhc-bispecifics-public-drivers/)

---
JSON: https://onco.cc/api/v1/entities/tscan.json